Genetic and Molecular Epidemiology (Modern epidemiology Chap. 28)

Chapter 28 Genetic and Molecular Epidemiology Muin J. Khoury, Robert
Millikan, and Marta Gwinn Chuntaro (@Shuntarooo3) 1 Modern Epidemiology

Genome? Gene? Omic 2 ਫౡ-ੁ໺७ࢠʢஶʣɾαΩϚΠίʢ࡞ըʣʢ2018ʣʰϚϯΨͰΘ͔Δ ήϊϜҩֶʱ༽౔ࣾɹ Λࢀߟʹ࡞੒ ճ Λ 䎠
࣏འ ڵ ↴ɾ ੨ɺ ᮊɾ ე 㥕 ࡉ๔ ֩ છ৭ମ %/" Ҩ఻ࢠ" Ҩ ఻ ࢠ # %/" N3/" λϯύΫ࣭ ήϊϜʢHFOPNFʣ ͋Δੜ෺͕΋ͭછ৭ମதʹ͋Δ ͢΂ͯͷ%/"഑ྻ৘ใͷ͜ͱ ʢશҨ఻৘ใʣ Ҩ఻ࢠʢHFOFʣ %/"ͷҰ෦Ͱɼʮ͜ͷ഑ྻʹ͠ ͕ͨͬͯλϯύΫ࣭Λ࡞Εʯͱ໋ ྩ͍ͯ͠Δ෦෼ͷ͜ͱ (FOPNJDT 1SPUFPNJDT w 5SBOTDSJQUPNJDT w .FUBCPOPNJDT w /VUSJHFOPNJDT w 1IBSNBDPHFOPNJDT w 5PYJDPHFOPNJDT 0NJD ͞·͟·ͳ໢ཏతੜମ෼ࢠΛ ·ͱΊͨ஌ࣝɾू߹ͷ͜ͱ

Genetic and Molecular Epidemiology 3 &YQPTVSFT 4VTDFQUJCJMJUZ 0VUDPNFT #JPMPHJDNBSLFST w
ײછ঱Ӹֶɿ߅ମՁ w ৺݂؅࣬ױӸֶɿ݂தࢷ࣭ w ؀ڥӸֶɿಟૉͷ݂தೱ౓ .PMFDVMBSFQJEFNJPMPHZʢ෼ࢠӸֶʣ (FOFUJDFQJEFNJPMPHZʢҨ఻Ӹֶʣ (FOFUJD GBDUPST 0VUDPNFT Wellcome Trust Case Control Consortium. (2007). Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature, 447(7145), 661. (FOF %JTFBTF %JTFBTF (FOF (FOF º (FOF &OWJSPONFOU º %JTFBTF

Overview 4 (FOF %JTFBTF %JTFBTF (FOF (FOF º (FOF &OWJSPONFOU
º %JTFBTF "OBMZUJDBOENFUIPEPMPHJDBMJTTVFT &YBNQMF w େ௎͕Μ w Ԍ঱ੑେ௎Ԍ %POPUDPWFSUSBEJUJPOBMHFOFUJDBOBMZTFT w Ոܥ෼ੳ w ࿈࠯ղੳ w Ϛοϐϯά

MULTIDISCIPLINARY APPROACHES TO THE EVALUATION OF BIOMARKERS (p. 566) 5
"OBMZUJDWBMJEJUZʢ෼ੳతଥ౰ੑʣ ͲͷΑ͏ͳόΠΦϚʔΧʔͰ͋ͬͯ΋ଥ౰ੑͷධՁ͸ඞཁ $MJOJDBMWBMJEJUZʢྟচతଥ౰ੑʣ $MJOJDBMVUJMJUZʢྟচత༗༻ੑʣ

ANALYTIC VALIDITY (p. 566) 6 "OBMZUJDWBMJEJUZ ʢ෼ੳతଥ౰ੑʣ "DDVSBDZ ʢਖ਼֬ੑʣ
Biomarker Test Present Absent + A B - C D = A A + C = D B + D "OBMZUJDTFOTJUJWJUZ ʢײ౓ʣ "OBMZUJDTQFDJpDJUZ ʢಛҟ౓ʣ ෼ੳతଥ౰ੑ͸ɼαϯϓϧͷछྨɼॲཧɼอଘ͓ΑͼΞοηΠͷଥ౰ੑʹґଘ͢Δ

CLINICAL VALIDITY (p. 566) 7 ෼ੳతଥ౰ੑΛ্ཱ֬ͨ͠Ͱɼ ࣍͸ྟচతଥ౰ੑΛྟচ͓ΑͼӸֶݚڀͰධՁ͢Δඞཁ͕͋Δ Clinical Outcome Biomarker
Present Absent + A B - C D = A A + C = D B + D $MJOJDBMTFOTJUJWJUZ ʢײ౓ʣ $MJOJDBMTQFDJpDJUZ ʢಛҟ౓ʣ = A A + B = D C + D 1PTJUJWFQSFEJDUJWFWBMVF ʢཅੑదத཰ʣ /FHBUJWFQSFEJDUJWFWBMVF ʢӄੑదத཰ʣ ࣬ױ͋Γͷݸମʹରͯ͠ ʢਖ਼͘͠ʣཅੑͱ਍அ͢Δ֬཰ ࣬ױͳ͠ͷݸମʹରͯ͠ ʢਖ਼͘͠ʣӄੑͱ਍அ͢Δ֬཰ ཅੑͱ਍அ͞Εͨݸମʹ͓͍ͯ ਅʹ࣬ױ͕ଘࡏ͢Δ֬཰ ӄੑͱ਍அ͞Εͨݸମʹ͓͍ͯ ਅʹ࣬ױ͕ଘࡏ͠ͳ͍֬཰

CLINICAL UTILITY (p. 567) 8 ྟচత༗༻ੑͱ͸ɼݕࠪʹΑΓΞ΢τΧϜ͕ྑ͘ͳΔ֬཰Λࣔ͢ #VSLFFUBM Outcome Intervention Sick
Not 1 A B 2 C D όΠΦϚʔΧʔ͕ཅੑͷݸମͷྟচత༗༻ੑධՁ ͜ͷද͸ɼόΠΦϚʔΧʔཅੑͷݸମʹରͯ͠ɼ ϥϯμϜʹ࣏ྍΛׂΓ౰ͯɼ࣏ྍͷޮՌΛධՁ͍ͯ͠Δ 3$5ˠ όΠΦϚʔΧʔͷྟচత༗༻ੑͷධՁʹͳ͍ͬͯΔʁ ?

ETHICAL, LEGAL, AND SOCIAL ISSUES (p. 567) 9 όΠΦϚʔΧʔʢಛʹҨ఻৘ใʣΛ࢖༻͢Δݚڀ͸ɼͨ͘͞Μͷ FUIJDBMʢྙཧతʣ
MFHBMʢ๏తʣ TPDJBMʢࣾձతʣͷJTTVFʢ՝୊ʣ E L S I w ΠϯϑΥʔϜυɾίϯηϯτ w ඃݧऀͷืू w ݚڀ݁Ռʹؔ͢Δ৘ใͷ։ࣔ w ݸਓ΍ूஂʹର͢ΔࠩผͷՄೳੑ

CONVENTIONAL EPIDEMIOLOGIC STUDIES (p. 568) 10 w $BTFDPOUSPMTUVEJFT w $PIPSUTUVEJFT
w $SPTTTFDUJPOBMTUVEJFT

AlleleɾGenotype 11 છ৭ମ A - T T - A G
- C C - G T - A ߏ଄Λ֦େ Ԙج഑ྻ %/" ˢ૬ิ࠯഑ྻ A A A A A A A a ෕༝དྷ ฼༝དྷ w ԘجͷόϦΤʔγϣϯΛΞϦϧʢBMMFMFʣ ͱ͍͏ w ΞϦϧͷ૊Έ߹Θͤ ʮ""PS"BPSBBʯΛδΣϊλΠϓ ʢHFOPUZQFʣͱ͍͏

SNV (Single Nucleotide Variant) 12 *% MPDVT MPDVT MPDVT MPDVT
MPDVT "" "" "" "" "" "" "" "( "" "" "" "" (( "" "" ௕͞ͷԘجΛ࠲ҐʢMPDVTʣͱ͢Δ େ൒͸ಉҰ w ͱ͖Ͳ͖ҟͳΔΞϦϧΛؚΉมҟʢόϦΞϯτɼWBSJBOUʣ͕͋Δ w ԘجͷόϦΞϯτ͸4/7ʢ4JOHMF/VDMFPUJEF7BSJBOUʣ

SNPɾMAF 13 δΣϊλΠϓ "" "B BB 5PUBM /
͋Δूஂʢ໊ʣͷ͋Δ4/7Λߟ͑Δ ΞϦϧ " B 5PUBM / ස౓ º º ϚΠφʔΞϦϧස౓ ʢ."'NJOPSBMMFMF GSFRVFODZʣ ස౓ͷগͳ͍ΞϦϧ 4/1ʢҰԘجଟܕʣ."'㱢΍ͷ4/7ͷ͜ͱ

CASE-CONTROL STUDIES (1) (p. 568) 14 Ҩ఻ࢠϚʔΧʔ͸ײडੑҼࢠͱͯ҆͠ఆ͍ͯ͠ΔͨΊɼ DBTFDPOUSPMTUVEJFTʹద͍ͯ͠Δ 3FDBMMCJBT͸গͳ͍
4VTDFQUJCJMJUZʢײडੑʣͱ͸ʁ Ҩ఻ੑ࣬ױ ୯ҰҨ఻ࢠ࣬ױ ଟҨ఻ੑ࣬ױʢ͋Γ;Εͨ࣬ױɼෳࡶ࣬ױɼDPNNPOEJTFBTFʣ ͭͷ࠲ҐʹΑܾͬͯఆతʹӨڹ͞ΕΔ খ͍͞د༩౓Λ΋ͬͨଟ͘ͷҨ఻తཁҼʹΑͬͯදݱܕ͕ܾఆ͞ΕΔ ײडੑҼࢠʢTVTDFQUJCJMJUZGBDUPSʣ w $POUSPM܈ʹରͯ͠$BTF܈ͰόϦΞϯτͷස౓͕༗ҙʹߴ͍͕ɼ Ұൠͷ݈ৗਓ΋͠͹͠͹ͦͷόϦΞϯτΛ༗͢Δ w $BTF܈Ͱ͋ͬͯ΋όϦΞϯτ͕ͳ͍ݸମ΋͋ΓಘΔ

CASE-CONTROL STUDIES (2) (p. 568) 15 ͭͷόϦΞϯτͱ࣬ױͱͷؔ࿈͚ͩͰ͸ͳ͘ɼ ଞͷόϦΞϯτ΍ཁҼͱڞʹ࣬ױͱͷؔ࿈Λ୳ࡧͰ͖Δ w
(FOFHFOFJOUFSBDUJPO w (FOFFOWJSPONFOUJOUFSBDUJPO ·ΕͳΤϯυϙΠϯτʢ3BSFEJTFBTFʣʹద͍ͯ͠Δ

CASE-CONTROL STUDIES (3) (p. 568) 16 0VUDPNF : $PWBSJBUF &
4/1 ( 4/1 ( ʜ 4/1K ( w ήϊϜϫΠυؔ࿈ղੳʢ(8"4HFOPNFXJEFBTTPDJBUJPOTUVEZʣ w σβΠϯ͸έʔεɾίϯτϩʔϧݚڀ w ֤4/1ͱΞ΢τΧϜʢ஋ܗ࣭ʣͱͷؔ࿈Λݕ౼͢ΔϞσϧ w 4/1ͷ਺͚ͩݕఆΛ܁Γฦ͢ 4/1਺͸਺ेສʙ਺ઍສ

COHORT STUDIES (p. 568) 17 ͋Γ;Εͨ࣬ױͱؔ࿈͢ΔҨ఻ࢠΛൃݟ͢ΔͨΊʹ໾ཱͭ w ॎஅతͳඇৗʹେن໛ͳूஂ w όΠΦόϯΫͷཱ֬
Study Sample size Population Study Objectives Decode Genetics > 100,000 Iceland • ͋Γ;Εͨ࣬ױͷݪҼͱͳΔҨ఻ࢠͷಉఆ • ৽ༀͷ։ൃ౳ UK Biobank 500,000 Population sample of persons aged 45-69 y • Ҩ఻ࢠɼ؀ڥɼੜ׆ελΠϧͷ໾ׂ • Medical recordͱϦϯΫ CartaGene (Quebec) > 60,000 Population sample of persons aged 25-74 y • Ҩ఻ࢠɼ؀ڥɼੜ׆ελΠϧɼ Medical recordͱϦϯΫ Estonia Genome Project > 1,000,000 Estonian population • ͋Γ;Εͨ࣬ױͷݪҼͱͳΔҨ఻ࢠͷಉఆ • Medical recordͱϦϯΫ GenomeEUTwin ʙ800,000 twin pairs Twin cohorts from 7 European countries + Australia • Ҩ఻ࢠɼ؀ڥɼੜ׆ελΠϧͷ໾ׂ ॊೈʹෳࡶͳϝΧχζϜɾԾઆ ʹରԠͰ͖Δ

CROSS-SECTIONAL STUDIES (p. 569) 18 ௐࠪ࣌఺ʹ͓͚Δ࣬ױͷ༗ප཰΍ͦͷ࣬ױʹؔ࿈͢ΔҨ఻ࢠΛ୳ࡧͰ͖Δ

METHODOLOGIC ISSUES CONFOUNDING (p. 570) 19 ڵຯͷ͋ΔόϦΞϯτ ࣬ױ 3BDFFUIOJDJUZ ʢਓछຽ଒ੑʣ
ަབྷҼࢠ ަབྷҼࢠͷௐ੔ํ๏ -PHJTUJDSFHSFTTJPONPEFM :ˡ4/1 ڞมྔɹ㱺ɹ4/1ʹ͍ͭͯͷݕఆ :ˡ4/1 ڞมྔɹ㱺ɹ4/1ʹ͍ͭͯͷݕఆɹŋŋŋҎԼಉ༷ (FOPUZQFDPEJOH $PWBSJBUFT XIFSF Gi 2 {0, 1, 2} Ei logit[Pr(Yi = 1)] = logit[⇡i( 0, e, g)] = 0 + eEi + gGi ⇡i = Pr(Yi = 1)

GENOTYPE AND EXPOSURE MISCLASSIFICATION (1) (p. 570) 20 /POEJ⒎FSFOUJBMNJTDMBTTJpDBUJPOʢඇࠩҟޡ෼ྨʣ͸ όΠΦϚʔΧʔʢ஋ʣͱΞ΢τΧϜͱͷؔ࿈Λرऍ͢Δ
ଞͷม਺ͱແؔ܎ͳޡ෼ྨʢؔ܎͢Δͷ͸ࠩҟޡ෼ྨʣ$IBQ /VMMํ޲΁ಇ͘ ਖ਼֬ͳ෼ྨ ඇࠩҟ෼ྨΛͨ͠৔߹ (-)ͷ20%→(+) (-)ͷ20%→(+) (+)ͷ20%→(-) Biomarker Biomarker Biomarker Clinical outcome + - + - + - Present 250 450 360 360 410 290 Absent 100 900 720 280 740 260 Odds Ratio 5.0 2.4 2.0 Kenneth J. Rothman, ༁ʢຊా߶, ྛ༤Ұ, & ࠤ౻ت࿨ʣ. ϩεϚϯͷӸֶ ୈ2൛, 2013.ͷද7-6Λࢀߟʹ࡞੒

GENOTYPE AND EXPOSURE MISCLASSIFICATION (2) (p. 570) 21 w ࿈࠯ෆฏߧঢ়ଶ͕ڧ͍όϦΞϯτ͸ɼ࣬ױͱͷؔ࿈͕ڧ͘ͳΔ
w ੈ୅͕ܦͭʹͭΕɼ࿈࠯ෆฏߧঢ়ଶ͕ऑ͘ͳΓɼ࣬ױͱͷؔ࿈͸رऍ͞ΕΔ ୈੈ୅ Oੈ୅ ࣬ױͱؔ࿈ͷ͋ΔόϦΞϯτʢ"ʣ όϦΞϯτʢ"ʣͱڑ཭͕ۙ͘ɼOੈ୅ܦͬͯ΋࿈࠯ฏߧঢ়ଶʹͳ͍ w Ҩ఻ࢠ͸ɼݮ਺෼྾ͷࡍʹ૊Έ׵͑Λى͜͢ w ಉ͡છ৭ମͰɼڑ཭͕͍ۙҨ఻ࢠ࠲͸όϦΞϯτʢ"ʣͱ ηοτʹͳͬͯ఻ΘΔ w ͭͷҟͳΔόϦΞϯτͱͷؔ࿈ͷఔ౓Λ ࿈࠯ෆฏߧʢ-JOLBHFEFTFRVJMJCSJVNʣͱ͍͏ ʢ૬ؔΈ͍ͨͳ΋ͷʣ w ؔ࿈͕ڧ͍ͱ͖ɼ࿈࠯ෆฏߧ͸ڧ͍ ඇࠩҟޡ෼ྨʹΑΔ

GENE-ENVIRONMENT INTERACTION (1) (p. 570) 22 (FOFUJDGBDUPS ( EJTFBTF &OWJSPONFOUBMGBDUPS
& PS&YQPTVSF "MMIVNBOEJTFBTF͸Ҩ఻ͱ؀ڥཁҼͱͷ૬ޓ࡞༻͕ݪҼͰ͋Δ º .BSHJOBMʹධՁ͢Δͱɼ૬ޓ࡞༻͕ϚεΫ͞ΕΔ (FOFUJDGBDUPS ( EJTFBTF EJTFBTF &OWJSPONFOUBMGBDUPS & PS&YQPTVSF Ҩ఻ཁҼʹΑΔϦεΫ ؀ڥཁҼʹΑΔϦεΫ

GENE-ENVIRONMENT INTERACTION(2) (p. 570) 23 Exposure Geno- type Cases Controls
Contrast Odds ratio Main information - - A00 B00 A OR00 = 1.0 (Reference) Common reference - + A01 B01 B B vs. A OR01 = A01B00 /(A00B01) Genotype alone vs. none + - A10 B10 C C vs. A OR10 = A10B00 /(A00B10) Environmental factor alone vs. none + + A11 B11 D D vs. A OR11 = A11B00 /(A00B11) Join genotype and environmental factor vs. none Multiplicative interaction D/(B * C) Deviation from multiplicative modelʢ৐๏Ϟσϧʣof interaction Additive interaction D - (B + C - 1) Deviation from additive modelʢՃ๏Ϟσϧʣof interaction (FOF&OWJSPONFOU*OUFSBDUJPO"OBMZTJTJOB$BTF$POUSPM4UVEZ Ҩ఻؀ڥަޓ࡞༻ͷղੳ͸͜ͷද͕͓͢͢Ί w ৘ใͷϩε͕ͳ͍ w ަޓ࡞༻ͷد༩͕෼͔Δ w ૉͷ৘ใ͕͋Δ͔Βɼ৴པ۠ؒ౳ͷܭࢉ΋Մೳ

EMERGING ANALYTIC COMPLEXITY(1) (p. 571) 24 ِཅੑͷ੍ޚʢଟॏੑͷ໰୊ʣ w (8"4Ͱ͸ଟ͘ͷ4/7ʹ͍ͭͯݕఆΛ͓͜ͳ͏ˠଟॏੑͷ໰୊ w
#POGFSSPOJิਖ਼Ͱ͸ɼ༗ҙਫ४͸º w ϕΠζతख๏΋։ൃ͞Ε͍ͯΔ খඪຊߴ࣍ݩσʔλ w QO໰୊ w ม਺ʹൺֱͯ͠αϯϓϧαΠζ͕খ͍͞ w ݟ্͔͚׬શʹ༧ଌͰ͖ΔϞσϧʢཁҼͷ૊Έ߹Θͤʣ͕๲େʹಘΒΕͯ͠ ·͏ w ࣍ݩͷढ͍ w ૊Έ߹ΘͤʢHFOFHFOF HFOFFOWJSPONFOUBMJOUFSBDUJPOʣ͕രൃతʹ૿ ͑Δ

EMERGING ANALYTIC COMPLEXITY(2) (p. 571) 25 /PWFMBOBMZUJDTUSBUFHJFT w ֊૚ܕճؼ෼ੳ w
ϕΠζਪఆ w $PNCJOBUPSJBMQBSUJUJPOJOHNFUIPE $1. w .VMUJGBDUPSEJNFOTJPOBMJUZSFEVDUJPO .%3 NFUIPE Flanders, W. D., & Khoury, M. J. (1996). Analysis of case-parental control studies: method for the study of associations between disease and genetic markers. American Journal of Epidemiology, 144(7), 696–703.

NONCONVENTIONAL EPIDEMIOLOGIC STUDIES (p. 573) 26 w $BTFPOMZTUVEJFT w $BTFQBSFOUTUVEJFT

CASE-ONLY STUDIES (p. 573) 27 $BTFPOMZEFTJHOʹ͍ͭͯ͸ɼ%S,*%ઌੜͷαΠτΛࢀߟʹͤͯ͞ ͍͖ͨͩ·ͨ͠ $BTF0OMZ%FTJHOʹ͍ͭͯʦҨ఻Ӹֶʧʛ(FOF&OWJSPONFOUBM*OUFSBDUJPO ʢIUUQTXXXESLJEOFUDBTFPOMZHFOFQJʣ w
$BTFͷΈΛର৅ʹݚڀΛ͓͜ͳ͏ํ๏ w (FOFHFOF (FOFFOWJSPONFOUBMJOUFSBDUJPOΛධՁͰ͖Δ Exposure Genotype Cases - - A00 - + A01 + - A10 + + A11 Case-only odds ratio = (A11A00)/(A10A01) ΑΓେ͖͍ͱ͖ɼ ަޓ࡞༻ͷՄೳੑ͕ࣔࠦ͞ΕΔ w .BJOF⒎FDUʢҨ఻ࢠ΍؀ڥ͕Ξ΢τΧϜʹ௚઀༩͑ΔӨڹʣ͸Θ͔Βͳ͍ w Ҩ఻ࢠͱ؀ڥཁҼ͕ಠཱ͍ͯ͠Δඞཁ͕͋Δ

CASE-PARENT STUDIES (p. 575) 28 $BTF $POUSPM w ࣬ױΛൃ঱ͨ͠$BTFͷ਌Λ$POUSPMͱ͢ΔσβΠϯ w
ਓछɼຽ଒ɼҨ఻తഎܠͱ͍ͬͨަབྷҼࢠΛऔΓআ͘͜ͱ͕Ͱ͖Δ w $BTFDPIPSUσβΠϯͷྨܕ Genotype + - Case A B Control C D

EXAMPLE 1: COLORECTAL CANCER (p. 575) 29 ߴස౓ͷ೑ͷઁऔ େ௎͕Μ )FUFSPDZMJDBNJOFT
)$"T ൃ͕Μੑ෺࣭ ैདྷͷӸֶ Ո଒ྺ հೖʹΑΓϦεΫ௿Լ Ҩ఻ࢠมҟ ΑΓऑ͍Ҩ఻ࢠมҟ ؀ڥཁҼ º Ҩ఻Ӹֶɾ෼ࢠӸֶ Ҩ఻ࢠ εΫϦʔχϯά ศதͷಛҟతͳ Ҩ఻ࢠมҟ ૣظൃݟ Ҩ఻ࢠϓϩϑΝΠϦϯά w αϒλΠϓʹ෼ྨ w ద੾ͳ࣏ྍΛબ୒

EXAMPLE 2: INFLAMMATORY BOWEL DISEASE (1) (p. 577) 30 w
Ԍ঱ੑ௎࣬ױͱͯ͠Ϋϩʔϯපͱ௵ᙾੑେ௎ԌΛѻ͏ w (8"4͕੒ޭΛऩΊͨ࣬ױ w (8"4ͷ݁Ռ͸ɼൃ঱ػংͷ࠶ߟΛଅͨ͠ w ૊৫ଛইΛҾ͖ى͜͢৽ͨͳ෺࣭ͷൃݟ w Ϋϩʔϯපͷ࣏ྍ๏ͱͯ͠ *-ʹର͢ΔϞϊΫϩφʔϧ߅ମΛ࢖༻ͨ͠ྟচࢼݧͷ࣮ࢪΛଅͨ͠ ؔ࿈όϦΞϯτͷ਺ ࣬ױ 2007೥ΑΓલʹಉఆ͞Εͨ όϦΞϯτ 2007೥͔Β2013೥த·Ͱʹಉఆ ͞ΕͨόϦΞϯτ Ϋϩʔϯප 3 (NOD2, IBD5, IL23R) 140 ௵ᙾੑେ௎Ԍ 1 (IL23R) 133 ଟൃੑߗԽ঱ 0 52 ݪൃੑ୾ोੑ؊ߗม 0 28 ؔઅϦ΢Ϛν 2 (PAD14, CTLA4) 30 શ਎ੑΤϦςϚτʔσε 2 (PTPN22, IR5) 31 1ܕ౶೘ප 3 (INS, PTPN22, IRF5) 40 ೥ʹ࠷ॳͷ(8"4͕ൃද͞Εͨ Tom Strachan et al., ༁ʢੁ໺७෉, & ෱ౢٛޫʣ. Genetics and Genomics in MedicineʢήϊϜҩֶʣ, 2016.ͷද8.10Λࢀߟʹ࡞੒

ࢀߟจݙ ,FOOFUI+3PUINBO ༁ʢຊా߶ ྛ༤Ұ ࠤ౻ت࿨ʣϩεϚϯͷӸֶୈ൛ ࣰݪग़ ൛৽ࣾ 5PN4USBDIBOFUBM
༁ʢੁ໺७෉ ෱ౢٛޫʣήϊϜҩֶ ϝσΟΧϧɾαΠΤϯεɾ Πϯλʔφγϣφϧ ਫౡੁ໺७ࢠʢஶʣɾαΩϚΠίʢ࡞ըʣϚϯΨͰΘ͔ΔήϊϜҩֶ ༽౔ࣾ "OESFB4'PVMLFT ؂༁ʢ੢ࢁؽʣ࣮ફͰΘ͔Δʂ3ʹΑΔ౷ܭҨ఻ֶ ؙળग़൛ ෌ా੣ ২໦༏෉ήϊϜσʔλղੳ ڞཱग़൛ ాٶݩ ২໦༏෉ খ৿ཧήϊϜҩֶͷͨΊͷҨ఻౷ܭֶ ڞཱग़൛ 31

Discussion!! 32

Genetic and Molecular Epidemiology (Modern epid...

Genetic and Molecular Epidemiology (Modern epidemiology Chap. 28)

Shuntaro Sato

More Decks by Shuntaro Sato

Other Decks in Science

Featured

Transcript

Chapter 28 Genetic and Molecular Epidemiology Muin J. Khoury, Robert

Genome? Gene? Omic 2 ਫౡ-ੁ໺७ࢠʢஶʣɾαΩϚΠίʢ࡞ըʣʢ2018ʣʰϚϯΨͰΘ͔Δ ήϊϜҩֶʱ༽౔ࣾɹ Λࢀߟʹ࡞੒ ճ Λ 䎠

Genetic and Molecular Epidemiology 3 &YQPTVSFT 4VTDFQUJCJMJUZ 0VUDPNFT #JPMPHJDNBSLFST w

Overview 4 (FOF %JTFBTF %JTFBTF (FOF (FOF º (FOF &OWJSPONFOU

MULTIDISCIPLINARY APPROACHES TO THE EVALUATION OF BIOMARKERS (p. 566) 5

ANALYTIC VALIDITY (p. 566) 6 "OBMZUJDWBMJEJUZ ʢ෼ੳతଥ౰ੑʣ "DDVSBDZ ʢਖ਼֬ੑʣ

CLINICAL VALIDITY (p. 566) 7 ෼ੳతଥ౰ੑΛ্ཱ֬ͨ͠Ͱɼ ࣍͸ྟচతଥ౰ੑΛྟচ͓ΑͼӸֶݚڀͰධՁ͢Δඞཁ͕͋Δ Clinical Outcome Biomarker

CLINICAL UTILITY (p. 567) 8 ྟচత༗༻ੑͱ͸ɼݕࠪʹΑΓΞ΢τΧϜ͕ྑ͘ͳΔ֬཰Λࣔ͢ #VSLFFUBM Outcome Intervention Sick

ETHICAL, LEGAL, AND SOCIAL ISSUES (p. 567) 9 όΠΦϚʔΧʔʢಛʹҨ఻৘ใʣΛ࢖༻͢Δݚڀ͸ɼͨ͘͞Μͷ FUIJDBMʢྙཧతʣ

CONVENTIONAL EPIDEMIOLOGIC STUDIES (p. 568) 10 w $BTFDPOUSPMTUVEJFT w $PIPSUTUVEJFT

AlleleɾGenotype 11 છ৭ମ A - T T - A G

SNV (Single Nucleotide Variant) 12 *% MPDVT MPDVT MPDVT MPDVT

SNPɾMAF 13 δΣϊλΠϓ "" "B BB 5PUBM /

CASE-CONTROL STUDIES (1) (p. 568) 14 Ҩ఻ࢠϚʔΧʔ͸ײडੑҼࢠͱͯ҆͠ఆ͍ͯ͠ΔͨΊɼ DBTFDPOUSPMTUVEJFTʹద͍ͯ͠Δ 3FDBMMCJBT͸গͳ͍

CASE-CONTROL STUDIES (2) (p. 568) 15 ͭͷόϦΞϯτͱ࣬ױͱͷؔ࿈͚ͩͰ͸ͳ͘ɼ ଞͷόϦΞϯτ΍ཁҼͱڞʹ࣬ױͱͷؔ࿈Λ୳ࡧͰ͖Δ w

CASE-CONTROL STUDIES (3) (p. 568) 16 0VUDPNF : $PWBSJBUF &

COHORT STUDIES (p. 568) 17 ͋Γ;Εͨ࣬ױͱؔ࿈͢ΔҨ఻ࢠΛൃݟ͢ΔͨΊʹ໾ཱͭ w ॎஅతͳඇৗʹେن໛ͳूஂ w όΠΦόϯΫͷཱ֬

CROSS-SECTIONAL STUDIES (p. 569) 18 ௐࠪ࣌఺ʹ͓͚Δ࣬ױͷ༗ප཰΍ͦͷ࣬ױʹؔ࿈͢ΔҨ఻ࢠΛ୳ࡧͰ͖Δ

METHODOLOGIC ISSUES CONFOUNDING (p. 570) 19 ڵຯͷ͋ΔόϦΞϯτ ࣬ױ 3BDFFUIOJDJUZ ʢਓछຽ଒ੑʣ

GENOTYPE AND EXPOSURE MISCLASSIFICATION (1) (p. 570) 20 /POEJ⒎FSFOUJBMNJTDMBTTJpDBUJPOʢඇࠩҟޡ෼ྨʣ͸ όΠΦϚʔΧʔʢ஋ʣͱΞ΢τΧϜͱͷؔ࿈Λرऍ͢Δ

GENOTYPE AND EXPOSURE MISCLASSIFICATION (2) (p. 570) 21 w ࿈࠯ෆฏߧঢ়ଶ͕ڧ͍όϦΞϯτ͸ɼ࣬ױͱͷؔ࿈͕ڧ͘ͳΔ

GENE-ENVIRONMENT INTERACTION (1) (p. 570) 22 (FOFUJDGBDUPS ( EJTFBTF &OWJSPONFOUBMGBDUPS

GENE-ENVIRONMENT INTERACTION(2) (p. 570) 23 Exposure Geno- type Cases Controls

EMERGING ANALYTIC COMPLEXITY(1) (p. 571) 24 ِཅੑͷ੍ޚʢଟॏੑͷ໰୊ʣ w (8"4Ͱ͸ଟ͘ͷ4/7ʹ͍ͭͯݕఆΛ͓͜ͳ͏ˠଟॏੑͷ໰୊ w

EMERGING ANALYTIC COMPLEXITY(2) (p. 571) 25 /PWFMBOBMZUJDTUSBUFHJFT w ֊૚ܕճؼ෼ੳ w

NONCONVENTIONAL EPIDEMIOLOGIC STUDIES (p. 573) 26 w $BTFPOMZTUVEJFT w $BTFQBSFOUTUVEJFT

CASE-ONLY STUDIES (p. 573) 27 $BTFPOMZEFTJHOʹ͍ͭͯ͸ɼ%S,%ઌੜͷαΠτΛࢀߟʹͤͯ͞ ͍͖ͨͩ·ͨ͠ $BTF0OMZ%FTJHOʹ͍ͭͯʦҨ఻Ӹֶʧʛ(FOF&OWJSPONFOUBMOUFSBDUJPO ʢIUUQTXXXESLJEOFUDBTFPOMZHFOFQJʣ w

CASE-PARENT STUDIES (p. 575) 28 $BTF $POUSPM w ࣬ױΛൃ঱ͨ͠$BTFͷ਌Λ$POUSPMͱ͢ΔσβΠϯ w

EXAMPLE 1: COLORECTAL CANCER (p. 575) 29 ߴස౓ͷ೑ͷઁऔ େ௎͕Μ )FUFSPDZMJDBNJOFT

EXAMPLE 2: INFLAMMATORY BOWEL DISEASE (1) (p. 577) 30 w

ࢀߟจݙ ,FOOFUI+3PUINBO ༁ʢຊా߶ ྛ༤Ұ ࠤ౻ت࿨ʣϩεϚϯͷӸֶୈ൛ ࣰݪग़ ൛৽ࣾ 5PN4USBDIBOFUBM

Discussion!! 32